• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

IL-23/IL-17 通路在风湿性疾病中的作用:概述。

Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview.

机构信息

Rheumatology Section, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University Hospital "P. Giaccone", Palermo, Italy.

Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.

出版信息

Front Immunol. 2021 Feb 22;12:637829. doi: 10.3389/fimmu.2021.637829. eCollection 2021.

DOI:10.3389/fimmu.2021.637829
PMID:33692806
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7937623/
Abstract

Interleukin-23 (IL-23) is a pro-inflammatory cytokine composed of two subunits, IL-23A (p19) and IL-12/23B (p40), the latter shared with Interleukin-12 (IL-12). IL-23 is mainly produced by macrophages and dendritic cells, in response to exogenous or endogenous signals, and drives the differentiation and activation of T helper 17 (Th17) cells with subsequent production of IL-17A, IL-17F, IL-6, IL-22, and tumor necrosis factor α (TNF-α). Although IL-23 plays a pivotal role in the protective immune response to bacterial and fungal infections, its dysregulation has been shown to exacerbate chronic immune-mediated inflammation. Well-established experimental data support the concept that IL-23/IL-17 axis activation contributes to the development of several inflammatory diseases, such as PsA, Psoriasis, Psoriatic Arthritis; AS, Ankylosing Spondylitis; IBD, Inflammatory Bowel Disease; RA, Rheumatoid Arthritis; SS, Sjogren Syndrome; MS, Multiple Sclerosis. As a result, emerging clinical studies have focused on the blockade of this pathogenic axis as a promising therapeutic target in several autoimmune disorders; nevertheless, a greater understanding of its contribution still requires further investigation. This review aims to elucidate the most recent studies and literature data on the pathogenetic role of IL-23 and Th17 cells in inflammatory rheumatic diseases.

摘要

白细胞介素-23 (IL-23) 是一种促炎细胞因子,由两个亚基组成,IL-23A (p19) 和 IL-12/23B (p40),后者与白细胞介素-12 (IL-12) 共享。IL-23 主要由巨噬细胞和树突状细胞在对外源或内源性信号作出反应时产生,驱动 T 辅助 17 (Th17) 细胞的分化和激活,随后产生白细胞介素-17A、白细胞介素-17F、白细胞介素-6、白细胞介素-22 和肿瘤坏死因子-α (TNF-α)。尽管 IL-23 在对细菌和真菌感染的保护性免疫反应中起着关键作用,但它的失调已被证明会加剧慢性免疫介导的炎症。成熟的实验数据支持这样一种观点,即 IL-23/IL-17 轴的激活有助于几种炎症性疾病的发展,如银屑病关节炎、银屑病、银屑病关节炎;强直性脊柱炎;炎症性肠病;类风湿关节炎;干燥综合征;多发性硬化症。因此,新兴的临床研究集中在阻断这一致病轴作为几种自身免疫性疾病的有希望的治疗靶点;然而,要更好地了解其贡献仍需要进一步的研究。这篇综述旨在阐明关于白细胞介素-23 和 Th17 细胞在炎症性风湿性疾病中的发病作用的最新研究和文献数据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b214/7937623/c6f714820e97/fimmu-12-637829-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b214/7937623/f5ef77d5f258/fimmu-12-637829-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b214/7937623/c6f714820e97/fimmu-12-637829-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b214/7937623/f5ef77d5f258/fimmu-12-637829-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b214/7937623/c6f714820e97/fimmu-12-637829-g0002.jpg

相似文献

1
Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview.IL-23/IL-17 通路在风湿性疾病中的作用:概述。
Front Immunol. 2021 Feb 22;12:637829. doi: 10.3389/fimmu.2021.637829. eCollection 2021.
2
Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases.辅助性 T 细胞 17 及其相关细胞因子在牙周炎和免疫介导性炎症疾病发病机制中的作用。
Int J Mol Sci. 2019 Jul 10;20(14):3394. doi: 10.3390/ijms20143394.
3
The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases.IL23/Th17通路作为慢性炎症性疾病的治疗靶点。
Inflamm Allergy Drug Targets. 2012 Apr;11(2):159-68. doi: 10.2174/187152812800392805.
4
Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases.辅助性T细胞17相关细胞因子白细胞介素-17、白细胞介素-22和白细胞介素-23在炎症性疾病中的关键作用。
Clin Dev Immunol. 2013;2013:968549. doi: 10.1155/2013/968549. Epub 2013 Jul 14.
5
The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases.IL-23 独立产生 IL-17F 和 IL-17A 的范式及其在慢性炎症性疾病中的作用。
Front Immunol. 2023 Aug 4;14:1191782. doi: 10.3389/fimmu.2023.1191782. eCollection 2023.
6
Interleukin-23: a key cytokine in inflammatory diseases.白细胞介素-23:炎症性疾病中的关键细胞因子。
Ann Med. 2011 Nov;43(7):503-11. doi: 10.3109/07853890.2011.577093. Epub 2011 May 17.
7
IL-23/IL-17 Axis in Inflammatory Rheumatic Diseases.IL-23/IL-17 轴在炎症性风湿病中的作用。
Clin Rev Allergy Immunol. 2021 Feb;60(1):31-45. doi: 10.1007/s12016-020-08823-4. Epub 2020 Nov 13.
8
The role of IL 23 in the treatment of psoriasis.白细胞介素23在银屑病治疗中的作用。
Expert Rev Clin Immunol. 2017 Jun;13(6):525-534. doi: 10.1080/1744666X.2017.1292137. Epub 2017 Feb 20.
9
The role of Th17 cells in psoriasis.Th17 细胞在银屑病中的作用。
Immunol Res. 2020 Oct;68(5):296-309. doi: 10.1007/s12026-020-09149-1. Epub 2020 Aug 22.
10
IL-23/IL-17A axis correlates with the nitric oxide pathway in inflammatory bowel disease: immunomodulatory effect of retinoic acid.白细胞介素-23/白细胞介素-17A 轴与炎症性肠病中的一氧化氮途径相关:维甲酸的免疫调节作用。
J Interferon Cytokine Res. 2013 Jul;33(7):355-68. doi: 10.1089/jir.2012.0063. Epub 2013 Mar 8.

引用本文的文献

1
Advances of bispecific antibodies using/application in dermatology: a review.双特异性抗体在皮肤病学中的应用进展:综述
Front Allergy. 2025 Aug 20;6:1668931. doi: 10.3389/falgy.2025.1668931. eCollection 2025.
2
Gut microbiota and ankylosing spondylitis: current insights and future challenges.肠道微生物群与强直性脊柱炎:当前见解与未来挑战。
Microb Cell. 2025 Aug 25;12:210-230. doi: 10.15698/mic2025.08.857. eCollection 2025.
3
A Common Genetic Background for Psoriasis and Cardiovascular Diseases: A Narrative Review.银屑病与心血管疾病的共同遗传背景:一篇综述

本文引用的文献

1
Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial.原发性干燥综合征中白细胞介素 6 受体抑制:一项多中心、双盲、随机、安慰剂对照试验。
Ann Rheum Dis. 2021 Mar;80(3):329-338. doi: 10.1136/annrheumdis-2020-218467. Epub 2020 Nov 18.
2
The Role of the IL-23/IL-17 Pathway in the Pathogenesis of Spondyloarthritis.白细胞介素-23/白细胞介素-17 通路在脊柱关节炎发病机制中的作用。
Int J Mol Sci. 2020 Sep 3;21(17):6401. doi: 10.3390/ijms21176401.
3
Treatment of Axial Spondyloarthritis: What Does the Future Hold?
Health Sci Rep. 2025 Aug 13;8(8):e71128. doi: 10.1002/hsr2.71128. eCollection 2025 Aug.
4
Comparative Analysis of the Long-Term Real-World Efficacy of Interleukin-17 Inhibitors in a Cohort of Patients with Moderate-to-Severe Psoriasis Treated in Poland.波兰中度至重度银屑病患者队列中白细胞介素-17抑制剂长期真实世界疗效的比较分析
J Clin Med. 2025 Aug 1;14(15):5421. doi: 10.3390/jcm14155421.
5
The IL-12 family cytokines in neurodegenerative diseases: dual roles in neurotoxicity and neuroprotection.神经退行性疾病中的白细胞介素-12家族细胞因子:在神经毒性和神经保护中的双重作用
Inflammopharmacology. 2025 Aug 13. doi: 10.1007/s10787-025-01901-z.
6
Identification of STAT3 and BIRC5 as anoikis-related biomarkers in psoriasis.鉴定STAT3和BIRC5作为银屑病中失巢凋亡相关生物标志物
Sci Rep. 2025 Aug 7;15(1):28929. doi: 10.1038/s41598-025-13992-3.
7
Multi-target drug discovery for rheumatoid arthritis: a comprehensive computational approach using bioactive compounds.类风湿性关节炎的多靶点药物发现:一种使用生物活性化合物的综合计算方法。
Sci Rep. 2025 Jul 28;15(1):27516. doi: 10.1038/s41598-025-12666-4.
8
Construction of a glycolysis-related diagnostic model for osteoarthritis through integrated bioinformatics analysis and machine learning.通过综合生物信息学分析和机器学习构建骨关节炎的糖酵解相关诊断模型
J Orthop Surg Res. 2025 Jul 11;20(1):639. doi: 10.1186/s13018-025-06072-9.
9
Common inherited loss-of-function mutations in the innate sensor NOD2 contribute to exceptional immune response to cancer immunotherapy.先天性传感器NOD2中常见的遗传性功能丧失突变有助于对癌症免疫疗法产生特殊的免疫反应。
Proc Natl Acad Sci U S A. 2025 Jul 15;122(28):e2314258122. doi: 10.1073/pnas.2314258122. Epub 2025 Jul 7.
10
Interleukin-17 and interleukin-23 cytokine profiles in palindromic rheumatism: potential therapeutic targets and prognostic biomarkers for disease progression to rheumatoid arthritis.复发性风湿症中白细胞介素-17和白细胞介素-23细胞因子谱:疾病进展为类风湿关节炎的潜在治疗靶点和预后生物标志物
Mol Biol Rep. 2025 Jul 3;52(1):672. doi: 10.1007/s11033-025-10786-8.
治疗中轴型脊柱关节炎:未来如何?
Curr Rheumatol Rep. 2020 Jul 20;22(9):47. doi: 10.1007/s11926-020-00924-5.
4
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study.倍美克单抗治疗活动期强直性脊柱炎患者的白细胞介素-17A 和白细胞介素-17F 的双阻断作用:一项 48 周、随机、双盲、安慰剂对照、剂量范围研究的结果。
Ann Rheum Dis. 2020 May;79(5):595-604. doi: 10.1136/annrheumdis-2020-216980. Epub 2020 Apr 6.
5
A novel treatment for psoriatic arthritis: Janus kinase inhibitors.银屑病关节炎的一种新型治疗方法:Janus激酶抑制剂。
Chin Med J (Engl). 2020 Apr 20;133(8):959-967. doi: 10.1097/CM9.0000000000000711.
6
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Guselkumab 在生物制剂初治的活动性银屑病关节炎患者中的疗效(DISCOVER-2):一项双盲、随机、安慰剂对照的 3 期临床试验。
Lancet. 2020 Apr 4;395(10230):1126-1136. doi: 10.1016/S0140-6736(20)30263-4. Epub 2020 Mar 13.
7
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.古塞单抗治疗生物制剂初治或既往接受 TNFα 抑制剂治疗的活动性银屑病关节炎患者(DISCOVER-1):一项双盲、随机、安慰剂对照的 3 期临床试验。
Lancet. 2020 Apr 4;395(10230):1115-1125. doi: 10.1016/S0140-6736(20)30265-8. Epub 2020 Mar 13.
8
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.依奇珠单抗治疗非放射性轴性脊柱关节炎(COAST-X)的随机、安慰剂对照试验。
Lancet. 2020 Jan 4;395(10217):53-64. doi: 10.1016/S0140-6736(19)32971-X. Epub 2019 Dec 5.
9
Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies.白细胞介素 (IL)-17 在炎症和免疫性疾病中的关键作用:聚焦争议的证据更新综述。
Autoimmun Rev. 2020 Jan;19(1):102429. doi: 10.1016/j.autrev.2019.102429. Epub 2019 Nov 15.
10
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.乌帕替尼治疗活动性强直性脊柱炎患者的疗效和安全性(SELECT-AXIS 1):一项多中心、随机、双盲、安慰剂对照、2/3 期临床试验。
Lancet. 2019 Dec 7;394(10214):2108-2117. doi: 10.1016/S0140-6736(19)32534-6. Epub 2019 Nov 12.